BRIEF-Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab

Reuters

03 Feb

BRIEF-Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab

Feb 3 (Reuters) - AnaptysBio Inc ANAB.O:

VANDA PHARMACEUTICALS AND ANAPTYS ANNOUNCE EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR VANDA TO DEVELOP AND COMMERCIALIZE IMSIDOLIMAB, AN IL-36R ANTAGONIST
VANDA PHARMACEUTICALS INC: VANDA EXPECTS TO IMMEDIATELY BEGIN PREPARING BLA AND MAA APPLICATIONS FOR US AND EU
VANDA PHARMACEUTICALS INC: ANAPTYS TO RECEIVE $15 MILLION FROM VANDA, COMPRISED OF A $10 MILLION UPFRONT PAYMENT AND $5 MILLION FOR EXISTING DRUG SUPPLY
VANDA PHARMACEUTICALS INC: ANAPTYS TO RECEIVE A 10% ROYALTY ON GLOBAL NET SALES OF IMSIDOLIMAB

Source text: ID:nPn5brdDta

Further company coverage: ANAB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2508110854"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2508110854\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2508110854?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-03 20:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2508110854","market":"us","top_or_hot":-1,"title":"BRIEF-Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Vanda, Anaptys Bio Enter into Global Deal TO Develop &amp; Market Imsidolimab </title></head><body><p><span>Feb 3 (Reuters)</span><span> - </span>AnaptysBio Inc <span>ANAB.O</span>:</p><ul><li><p>VANDA PHARMACEUTICALS AND ANAPTYS ANNOUNCE EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR VANDA TO DEVELOP AND COMMERCIALIZE IMSIDOLIMAB, AN IL-36R ANTAGONIST</p></li><li><p>VANDA PHARMACEUTICALS INC: VANDA EXPECTS TO IMMEDIATELY BEGIN PREPARING BLA AND MAA APPLICATIONS FOR US AND EU</p></li><li><p>VANDA PHARMACEUTICALS INC: ANAPTYS TO RECEIVE $15 MILLION FROM VANDA, COMPRISED OF A $10 MILLION UPFRONT PAYMENT AND $5 MILLION FOR EXISTING DRUG SUPPLY</p></li><li><p>VANDA PHARMACEUTICALS INC: ANAPTYS TO RECEIVE A 10% ROYALTY ON GLOBAL NET SALES OF IMSIDOLIMAB</p></li></ul><p>Source text: <span>ID:nPn5brdDta</span></p><p>Further company coverage: <span>ANAB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-03 20:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Vanda, Anaptys Bio Enter into Global Deal TO Develop &amp; Market Imsidolimab </title></head><body><p><span>Feb 3 (Reuters)</span><span> - </span>AnaptysBio Inc <span>ANAB.O</span>:</p><ul><li><p>VANDA PHARMACEUTICALS AND ANAPTYS ANNOUNCE EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR VANDA TO DEVELOP AND COMMERCIALIZE IMSIDOLIMAB, AN IL-36R ANTAGONIST</p></li><li><p>VANDA PHARMACEUTICALS INC: VANDA EXPECTS TO IMMEDIATELY BEGIN PREPARING BLA AND MAA APPLICATIONS FOR US AND EU</p></li><li><p>VANDA PHARMACEUTICALS INC: ANAPTYS TO RECEIVE $15 MILLION FROM VANDA, COMPRISED OF A $10 MILLION UPFRONT PAYMENT AND $5 MILLION FOR EXISTING DRUG SUPPLY</p></li><li><p>VANDA PHARMACEUTICALS INC: ANAPTYS TO RECEIVE A 10% ROYALTY ON GLOBAL NET SALES OF IMSIDOLIMAB</p></li></ul><p>Source text: <span>ID:nPn5brdDta</span></p><p>Further company coverage: <span>ANAB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VNDA","symbol_name":"万达生物制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA6MBNBS:1","article_id":"2508110854","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508110854","pubTimestamp":1738586958,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab Feb 3 (Reuters) - AnaptysBio Inc ANAB.O:VANDA PHARMACEUTICALS AND ANAPTYS ANNOUNCE EXCLUSIVE GLOBAL LICENSE AGREEMENT FO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VNDA":"万达生物制药","ANAB":"Anaptysbio Inc","BK4139":"生物科技"},"translate_title":"简介-Vanda与Anaptys Bio达成开发和营销Imsidolimab的全球协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANAB":0.9,"VNDA":0.9},"content_text":"BRIEF-Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab Feb 3 (Reuters) - AnaptysBio Inc ANAB.O:VANDA PHARMACEUTICALS AND ANAPTYS ANNOUNCE EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR VANDA TO DEVELOP AND COMMERCIALIZE IMSIDOLIMAB, AN IL-36R ANTAGONISTVANDA PHARMACEUTICALS INC: VANDA EXPECTS TO IMMEDIATELY BEGIN PREPARING BLA AND MAA APPLICATIONS FOR US AND EUVANDA PHARMACEUTICALS INC: ANAPTYS TO RECEIVE $15 MILLION FROM VANDA, COMPRISED OF A $10 MILLION UPFRONT PAYMENT AND $5 MILLION FOR EXISTING DRUG SUPPLYVANDA PHARMACEUTICALS INC: ANAPTYS TO RECEIVE A 10% ROYALTY ON GLOBAL NET SALES OF IMSIDOLIMABSource text: ID:nPn5brdDtaFurther company coverage: ANAB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1}}}